SCHEMBL3545383

SCHEMBL3545383

COC(=O)C(=O)Nc1ccc(N2CCN(C(=O)OC(C)(C)C)CC2)nc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.58
CRBN Q96SW2 1/20 0.58
WNT3A P56704 1/20 0.57
MAPT P10636 3/20 0.51
MEN1 O00255 1/20 0.51
TSHR P16473 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
GPR119 Q8TDV5 4/20 0.50
CKS1B P61024 2/20 0.49
SKP1 P63208 2/20 0.49
SKP2 Q13309 2/20 0.49
ALDH1A1 P00352 2/20 0.48
MAP4K4 O95819 1/20 0.47
KDM4E B2RXH2 1/20 0.47
DGAT1 O75907 1/20 0.47
PTPN11 Q06124 1/20 0.46
TBK1 Q9UHD2 1/20 0.46
NAMPT P43490 1/20 0.46
RET P07949 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5326030 0.85 PTPN11 (0.53) DDB1CRBNMAPTMEN1TSHR
SCHEMBL24590342 0.85 DDB1 (0.63) DDB1CRBNWNT3AMAPTMEN1
SCHEMBL27217400 0.84 DDB1 (0.58) DDB1CRBNWNT3AMAPTMEN1
SCHEMBL30261848 0.81 DDB1 (0.62) DDB1CRBNWNT3AMAPTMEN1
SCHEMBL28956351 0.81 DDB1 (0.62) DDB1CRBNWNT3AMAPTMEN1
SCHEMBL5471069 0.81 ALDH1A1 (0.54) DDB1CRBNWNT3AMAPTMEN1
SCHEMBL3086737 0.81 MAPT (0.54) DDB1CRBNWNT3AMAPTMEN1
SCHEMBL30893577 0.80 DDB1 (0.57) DDB1CRBNWNT3ASMN1; SMN2GPR119
SCHEMBL1905470 0.80 DDB1 (0.57) DDB1CRBNWNT3ASMN1; SMN2GPR119
SCHEMBL30313118 0.79 NPC1 (0.62) DDB1CRBNWNT3AKMT2AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 DDB1 1913/4885CRBN 3725/4885WNT3A 3210/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 DDB1 1864/4885CRBN 3979/4885WNT3A 3053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.